Acceleron Pharma Inc. (XLRN) Rises to $48.60

June 29, 2018 - By Heather Owens

Acceleron Pharma Inc. (NASDAQ:XLRN) Corporate Logo

Big Money Sentiment increased to 1.27 in 2018 Q1. It has change of 0.18, from 2017Q4’s 1.09. The ratio improved due to Acceleron Pharma Inc. positioning: 13 sold and 39 reduced. 24 funds bought stakes and 42 increased stakes. Investors holded 38.14 million in 2017Q4 but now own 38.30 million shares or 0.44% more.
Alliancebernstein Lp has invested 0% in Acceleron Pharma Inc. (NASDAQ:XLRN). Eagle Asset Mngmt invested in 0.26% or 1.23M shs. Jasper Ridge Ptnrs Lp has invested 0.03% of its capital in Acceleron Pharma Inc. (NASDAQ:XLRN). New York-based Morgan Stanley has invested 0% in Acceleron Pharma Inc. (NASDAQ:XLRN). Waddell Reed Fin reported 28,300 shs. Polar Cap Llp stated it has 1.07M shs or 0.42% of all its holdings. Aqr Management Ltd Liability Corporation has 0% invested in Acceleron Pharma Inc. (NASDAQ:XLRN) for 9,537 shs. California State Teachers Retirement System reported 57,172 shs. Axa has invested 0.04% in Acceleron Pharma Inc. (NASDAQ:XLRN). Credit Suisse Ag stated it has 51,468 shs. California Employees Retirement Systems holds 21,300 shs or 0% of its capital. Westfield Capital Ltd Partnership holds 0.41% or 1.37M shs in its capital. Pnc Financial Services Grp has invested 0.01% in Acceleron Pharma Inc. (NASDAQ:XLRN). Public Employees Retirement Association Of Colorado invested 0% of its capital in Acceleron Pharma Inc. (NASDAQ:XLRN). Deutsche Savings Bank Ag reported 467,876 shs stake.

Acceleron Pharma Inc. registered $4.08 million net activity with 0 insider purchases and 12 sales since January 2, 2018. Quisel John D sold $46,232 worth of stock or 1,204 shs. Rovaldi Christopher had sold 11,000 shs worth $495,000 on Friday, January 12. $814,848 worth of Acceleron Pharma Inc. (NASDAQ:XLRN) was sold by MCLAUGHLIN KEVIN F on Tuesday, January 2. $197,868 worth of Acceleron Pharma Inc. (NASDAQ:XLRN) was sold by Sherman Matthew L on Wednesday, January 3. POPS RICHARD F had sold 37,500 shs worth $1.55M on Tuesday, March 6.

Acceleron Pharma Inc. (NASDAQ:XLRN) increased significantly to $48.60. On Jun, 29 the move was announced by Barchart.com. It has $2.23 billion MC. The company’s valuation will be $66.75M more at $50.06 target.

Acceleron Pharma Inc. (NASDAQ:XLRN)’s quarterly earnings will be reported on August, 2., Zacks reports. Analysts have anticipation on stock’s EPS of $-0.64. That’s up 16.88 % from last year’s $-0.77 EPS. After $-0.58 EPS report previous quarter, Wall Street now predicts 10.34 % negative EPS growth of Acceleron Pharma Inc..

Acceleron Pharma Inc. (NASDAQ:XLRN) Ratings Coverage

In total 7 analysts cover Acceleron Pharma (NASDAQ:XLRN). “Buy” rating has 5, “Sell” are 0, while 2 are “Hold”. (NASDAQ:XLRN) has 71% bullish analysts. 9 are the (NASDAQ:XLRN)’s ratings reports on Jun 29, 2018 according to StockzIntelligence Inc. On Wednesday, February 28 the firm earned “Overweight” rating by Barclays Capital. The company rating was upgraded by Goldman Sachs on Friday, June 29. On Friday, June 29 the stock of Acceleron Pharma Inc. (NASDAQ:XLRN) has “Outperform” rating given by Credit Suisse. On Monday, February 26 the rating was upgraded by JP Morgan to “Overweight”. In Tuesday, May 22 report Oppenheimer initiated the stock with “Hold” rating. The company rating was maintained by Citigroup on Thursday, March 1. The company rating was initiated by H.C. Wainwright on Monday, January 8. On Wednesday, March 28 H.C. Wainwright initiated the shares of XLRN in report with “Buy” rating. On Wednesday, February 28 the company was maintained by H.C. Wainwright.

For more Acceleron Pharma Inc. (NASDAQ:XLRN) news published recently go to: Seekingalpha.com, Benzinga.com, Globenewswire.com, 247Wallst.com or Benzinga.com. The titles are as follows: “Acceleron: Luspatercept New Data Is A Buy Signal” published on June 07, 2018, “Acceleron Pharma Rallies After Phase 3 MDS Data, But Goldman Sachs Still Isn’t Buying” on June 29, 2018, “Market Trends Toward New Normal in RCI Hospitality, Phillips 66 Partners LP, Acceleron Pharma, Destination …” with a publish date: June 22, 2018, “Top Analyst Upgrades and Downgrades: Accenture, Ally, Diageo, Harley-Davidson, KB Home, NetApp, Nike, Sirius XM …” and the last “Benzinga’s Top Upgrades, Downgrades For June 29, 2018” with publication date: June 29, 2018.

Acceleron Pharma Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for serious and rare diseases.The firm is worth $2.23 billion. The Company’s therapeutic candidates include luspatercept to treat anemia and associated complications in patients with myelodysplastic syndromes and beta-thalassemia; and sotatercept for chronic kidney diseases.Currently it has negative earnings. The companyÂ’s therapeutic candidates also include dalantercept, a tyrosine kinase inhibitor, which is in phase II clinical trials for renal cell carcinoma; and ACE-083 that is in phase II clinical trials for facioscapulohumeral dystrophy.

Acceleron Pharma Inc. (NASDAQ:XLRN) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.